Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$27.43 USD
-2.88 (-9.50%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $27.40 -0.03 (-0.11%) 7:18 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
BEAM 27.43 -2.88(-9.50%)
Will BEAM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BEAM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BEAM
Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?
Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines
BEAM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Invest in Beam Therapeutics (BEAM) Now
Beam Therapeutics (BEAM) Upgraded to Buy: What Does It Mean for the Stock?
Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study
Other News for BEAM
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q2 2024 Update
iShares Biotechnology ETF: Significant Upside Potential As Sector Gains Momentum
Interesting BEAM Put And Call Options For September 20th
Why Is Conn’s (CONN) Stock Down 36% Today?
Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40